Skip to main content
SpringerLink
Log in

Breast Cancer Prevention

  • Chapter
Advances in Breast Cancer Management, Second Edition

Part of the book series: Cancer Treatment and Research ((CTAR,volume 141))

Breast cancer is a devastating illness that affects tens of thousands of American women each year. Although it is impossible to predict who will develop breast cancer, clinicians can identify women who are at increased risk for breast cancer and provide them with options to reduce their risk. A number of validated, quantitative risk-assessment models incorporate features of a patient’s medical and family history to help women more accurately estimate their individual risk and thus aid them in decision-making. Over the years, research has focused on the development of both surgical and medical methods for breast cancer risk reduction in high-risk women. This chapter will emphasize the importance of identifying and educating women at increased risk for breast cancer, and then providing them with a comprehensive breast cancer risk management plan. We will also discuss the surgical and medical options available and offer a management summary for breast cancer risk reduction.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Black, W. C., Nease Jr, R. F., Tosteson, A. N. A. 1995. Perceptions of breast cancer risk and screening effectiveness in women younger than 50 years of age. J Natl Cancer Inst 87:720–31.

    Article  PubMed  CAS  Google Scholar 

  2. Colditz, G. A., Rosner, B. 2000. Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses’ Health Study. Am J Epidemiol 152:950–64.

    Article  PubMed  CAS  Google Scholar 

  3. Vogel, V. G. 1998. Breast cancer risk factors and preventive approaches to breast cancer. In: Kavanagh J, Singletary SE, Einhorn N, et al., editors. Cancer in women. Cambridge (MA): Blackwell Scientific Publications, Inc., 58–91.

    Google Scholar 

  4. Vogel, VG, Bevers, T. Handbook of Breast Cancer Risk-Assessment. Evidence-Based Guidelines for Evaluation, Prevention, Counseling, and Treatment. Sudbury (MA): Jones and Bartlett Publishers; 2003.

    Google Scholar 

  5. Offit, K., Brown, K. 1994. Quantitation of familial cancer risk: a resource for clinical oncologists. J Clin Oncol 12:1724–36.

    PubMed  CAS  Google Scholar 

  6. Wooster, R., Neuhausen, S. L., Mangion, J., et al. 1994. Localization of a breast cancer susceptibility gene, BRCA2, to chromosomes 13q12–13. Science 265:2088–90.

    Article  PubMed  CAS  Google Scholar 

  7. Easton, D. F., Bishop, D. T., Ford, D., et al. 1993. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. Am J Hum Genet 52:678–701.

    PubMed  CAS  Google Scholar 

  8. Struewing, J. P., Hartge, P., Wacholder, S., et al. 1997. The risk of cancer associated with specific mutation of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336:1401–1408.

    Article  PubMed  CAS  Google Scholar 

  9. Dupont, W. D., Page, D. L., Parl, F. F., et al. 1994. Long-term risk of breast cancer in women with fibroadenoma. N Engl J Med 331:10–15.

    Article  PubMed  CAS  Google Scholar 

  10. London, S. J., Connolly, J. L., Schnitt, S. J., et al. 1992. A prospective study of benign breast disease and the risk of breast cancer. JAMA 267:941–4.

    Article  PubMed  CAS  Google Scholar 

  11. Dupont, W. D., Page, D. L. 1985. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 312:146–51.

    PubMed  CAS  Google Scholar 

  12. Dupont, W. D., Parl, F. F., Hartman, W. H., et al. 1993. Breast cancer risk associated with proliferative disease and atypical hyperplasia. Cancer 71:1258–65.

    Article  PubMed  CAS  Google Scholar 

  13. Page, D. L., Dupont, W. D., Rogers, L. W., et al. 1985. 1998. Atypical hyperplastic lesions of the female breast: a long-term follow-up study. Cancer 55:2698–708.

    Article  PubMed  CAS  Google Scholar 

  14. Fisher, B., Costantino, J. P., Wickerham, D. L., et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371–88.

    Google Scholar 

  15. Gail, M. H., et al. 1989. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81:1879–86.

    Article  PubMed  CAS  Google Scholar 

  16. Lehman, C. D., Gatsonis, C., Kuhl, C. K., et al. 2007. MRI Evaluation in the Contralateral Breast in Women with Recently Diagnosed Breast Cancer. N Engl J Med 356:1295–1303.

    Article  PubMed  CAS  Google Scholar 

  17. Hartmann, L. C., Schaid, D. J., Woods, J. E., et al. 1999. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 340:77–84.

    Article  PubMed  CAS  Google Scholar 

  18. Meijers-Heijboer, M., van Geel, B., van Putten, W. L. J., et al. 2001. Breast cancer after prophylactic bilateral mastectomy in women with BRCA1 or BRCA2 mutation. N Engl J Med 345:154–64.

    Article  Google Scholar 

  19. Kauff, N. D., Satagopan, J. M., Robson, M. E., et al. 2002. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346:1609–15.

    Article  PubMed  Google Scholar 

  20. Rebbeck, T. R., Lynch, H. T., Neuhausen, S. L., et al. 2002. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346:1616–22.

    Article  PubMed  Google Scholar 

  21. Cuzick, J., Powles, T., Veronesi, U., et al. 2003. Overview of the main outcomes in breast-cancer prevention trials. Lancet 361:296–300.

    Article  PubMed  CAS  Google Scholar 

  22. Osborne, C. K. 1989. Tamoxifen in the treatment of breast cancer. N Engl J Med 339:1609–18.

    Article  Google Scholar 

  23. Powles, T. J., Jones, A. L., Ashley, S. E., et al. 1994. The Royal Marsden Hospital pilot tamoxifen chemoprevention trial. Breast Cancer Res Treat 31:73–82.

    Article  PubMed  CAS  Google Scholar 

  24. Powles, T. J., Ashley, S., Tidy, A., et al. 2007. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst 99:283–90.

    Article  PubMed  CAS  Google Scholar 

  25. Veronesi, U., Maisonneuve, P., Sacchini, V., et al. 2002. Tamoxifen for breast cancer among hysterectomised women. Lancet 359:1122–24.

    Article  PubMed  CAS  Google Scholar 

  26. Veronesi, U., Maisonneuve, P., Rotmensz, N., et al. 2003. Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women. J Natl Cancer Inst 95:160–5.

    PubMed  CAS  Google Scholar 

  27. IBIS Investigators. 2002. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 360:817–24.

    Article  Google Scholar 

  28. Tyrer, J., Duffy, S. W., Cuzick, J. 2004. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 23:1111–30.

    Article  PubMed  Google Scholar 

  29. Cuzick, J., Forbes, J. F., Sestak, I., et al. for the International Breast Cancer Intervention Study (IBIS) I Investigators. 2007. Long-term results of tamoxifen prophylaxis for breast cancer-96 month follow-up of the randomized IBIS-I study. J Natl Cancer Inst 99:272–82.

    Article  PubMed  CAS  Google Scholar 

  30. Sato, M., Glasebrook, A. L., Bryant, H. U. 1994. Raloxifene: a selective estrogen receptor modulator. J Bone Miner Metab 12:S9–S20.

    Article  CAS  Google Scholar 

  31. Bryant, H. U., Glasebrook, A. L., Yang, N. N., et al. 1996. A pharmacological review of raloxifene. J Bone Miner Metab 14:1–9.

    Article  CAS  Google Scholar 

  32. Delmas, P. D., Bjarnason, N. H., Mitlak, B. H., et al. 1997. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337:1641–47.

    Article  PubMed  CAS  Google Scholar 

  33. Ettinger, B., Black, D. M., Mitlak, B. H., et al. 1999. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 282:637–45.

    Article  PubMed  CAS  Google Scholar 

  34. Cummings, S. R., Eckert, S., Krueger, K. A., et al. 1999. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. JAMA 281:2189–97.

    Article  PubMed  CAS  Google Scholar 

  35. Lippman, M. E., Krueger, K. A., Eckert, S., et al. 2001. Indicators of lifetime estrogen exposure: effect on breast cancer incidence and interaction with raloxifene therapy in the Multiple Outcomes of Raloxifene Evaluation study participants. J Clin Oncol 19:3111–16.

    PubMed  CAS  Google Scholar 

  36. Cummings, S. R., Duong, T., Kenyon, T., et al. 2002. Serum estradiol level and risk of breast cancer during treatment with raloxifene. JAMA 287:216–20.

    Article  PubMed  CAS  Google Scholar 

  37. Cauley, J. A., Norton, L., Lippman, M. E., et al. 2001. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Breast Cancer Res Treat 65:125–34.

    Article  PubMed  CAS  Google Scholar 

  38. Grady, D., Ettinger, B., Moscarelli, E., et al. 2004. Safety and adverse effects associated with raloxifene: Multiple Outcomes of Raloxifene Evaluation. Obstet Gynecol 104:837–44.

    PubMed  CAS  Google Scholar 

  39. Martino, S., Cauley, J. A., Barrett-Connor, E., et al. 2004. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 96:1751–61.

    PubMed  CAS  Google Scholar 

  40. Lippman, M. E., Cummings, S. R., Disch, D. P., et al. 2006. Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk. Clin Cancer Res 12:5242–47.

    Article  PubMed  CAS  Google Scholar 

  41. Barrett-Connor, E., Grady, D., Sashegyi, A., et al. 2002. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 287:847–57.

    Article  PubMed  CAS  Google Scholar 

  42. Ensrud, K., Genazzani, A. R., Geiger, M. J., et al. 2006. Effect of raloxifene on cardiovascular adverse events in postmenopausal women with osteoporosis. Am J Cardiol 97:520–27.

    Article  PubMed  CAS  Google Scholar 

  43. Barrett-Connor, E., Mosca, L., Collins, P., et al. 2006. Raloxifene Use for The Heart (RUTH) Trial Investigators. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355:125–37.

    Article  PubMed  CAS  Google Scholar 

  44. Vogel, V. G., Costantino, J. P., Wickerham, D. L., et al. 2006. National Surgical Adjuvant Breast and Bowel Project (NSABP). Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295:2727–41.

    Article  PubMed  CAS  Google Scholar 

  45. Day, R. 2001. Quality of life and tamoxifen in a breast cancer prevention trial: a summary of findings from the NSABP P-1 study. Ann N Y Acad Sci 949:143–150.

    Article  PubMed  CAS  Google Scholar 

  46. Land, S. R., Wickerham, D. L., Costantino, J. P., et al. 2006. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295:2742–51.

    Article  PubMed  CAS  Google Scholar 

  47. McHorney, C. A., Ware Jr, J. E., Lu, J. F., Sherbourne, C. D. 1994. The MOS 36-item Short-Form Health Survey (SF-36), III: tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care 32:40–66.

    Article  PubMed  CAS  Google Scholar 

  48. McHorney, C. A., Ware Jr, J. E., Raczek, A. E. 1993. The MOS 36-Item Short-Form Health Survey (SF-36), II: psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 31:247–63.

    Article  PubMed  CAS  Google Scholar 

  49. Ware, J. E. Jr, Sherbourne, C. D. 1992. The MOS 36-item short-form health survey (SF-36), I: conceptual framework and item selection. Med Care 30:473–83.

    Article  PubMed  Google Scholar 

  50. McHorney, C. A., Ware Jr, J. E., Rogers, W., et al. 1992. The validity and relative precision of MOS short- and long-form health status scales and Dartmouth COOP charts: results from the Medical Outcomes Study. Med Care 30(5 suppl):MS253–MS265.

    Article  PubMed  CAS  Google Scholar 

  51. Radloff, L.S. 1977. The CES-D Scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1:385–401.

    Article  Google Scholar 

  52. Sherbourne, C. D. 1992. Social functioning: sexual problems measures. In: Stewart AL, Ware JE, editors. Measuring functioning and well-being: The Medical Outcomes Study approach. Durham, NC: Duke University Press, 194–204.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, University of Pittsburgh, 200 Lothrop St, 15213, Pittsburgh, PA, USA

    Jennifer G. Reeder M.D.

  2. University of Pittsburgh School of Medicine, Magee-Womens Hospital, 300 Halket Street, 15213-3180, Pittsburgh, PA, USA

    Victor G. Vogel M.D., M.H.S, F.A.C.P.

Authors
  1. Jennifer G. Reeder M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Victor G. Vogel M.D., M.H.S, F.A.C.P.
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Northwestern University School of Medicine, 675 North St, 60611, Chicago, IL, USA

    William J. Gradishar M.D.

  2. Emory University School of Medicine, 201 Dowman Drive, 30322, Atlanta, GA, USA

    William C. Wood M.D.

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Reeder, J.G., Vogel, V.G. (2008). Breast Cancer Prevention. In: Gradishar, W.J., Wood, W.C. (eds) Advances in Breast Cancer Management, Second Edition. Cancer Treatment and Research, vol 141. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-73161-2_10

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-73161-2_10

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-387-73160-5

  • Online ISBN: 978-0-387-73161-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation